| ECL |
Report |
Adjusted diluted EPS (Q2'26) |
IN-LINE |
pred ~$2.09 vs. cons ~$2.08 |
MEDIUM |
| ECL |
Report |
Organic sales growth (Q2'26) |
IN-LINE |
pred ~4.0% vs. cons ~4.2% |
MEDIUM |
| ECL |
Report |
Adjusted operating margin (Q2'26) |
IN-LINE |
pred ~17.2% vs. cons ~17.3% |
LOW |
| ECL |
Guide |
FY2026 adj EPS guide (ex-CoolIT) |
UNCHANGED |
guide ~$8.43-$8.63 (mid $8.53) vs. cons ~$8.52 (FY2026) |
HIGH |
| ECL |
Guide |
Q3'26 adj EPS guide (incl. ~$0.20 CoolIT drag) |
LOWER |
guide ~$2.05-$2.15 reported vs. cons ~$2.22 pre-dilution (Q3'26) |
MEDIUM |
| ECL |
Guide |
H2'26 organic sales growth |
UNCHANGED |
guide ~6-7% vs. cons ~6% (H2 2026) |
MEDIUM |
| ECL |
Guide |
Price/cost exit-rate (pricing catches raws at Q2 exit) |
UNCHANGED |
guide ~fully offset by Q2 exit vs. cons ~fully offset (Q2/H2 2026) |
MEDIUM |
| ECL |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
MEDIUM |
| ECL |
Return |
5-day cumulative residual |
-3.0% (FADE) |
Even on an in-line print and a held ex-CoolIT FY guide, the out-period math is negative: CoolIT closes in Q3 and adds ~$0.20 of H2 dilution, so reported H2/Q3 estimates get cut once the reported-vs-underlying bridge is disclosed. Combined with a rich ~28x multiple, ECL's recurring 'sell-the-news' pattern (Q1 fell ~4% on an in-line beat), and the price/cost recovery being only a promise rather than proof, the modest day-1 drop follows through lower as estimates drift down. |
LOW |